Literature DB >> 19160207

Antibiotics for spontaneous bacterial peritonitis in cirrhotic patients.

Norberto C Chavez-Tapia1, Karla Soares-Weiser, Mayer Brezis, Leonard Leibovici.   

Abstract

BACKGROUND: Spontaneous bacterial peritonitis is a complication of cirrhotic ascites that occurs in the absence of any intra-abdominal, surgically treatable source of infection. Antibiotic therapy is indicated and should be initiated as soon as possible to avoid severe complications that may lead to death. It has been proposed that empirical treatment should cover gram-negative enteric bacteria and gram-positive cocci, responsible for up to 90% of spontaneous bacterial peritonitis cases.
OBJECTIVES: This review aims to evaluate the beneficial and harmful effects of different types and modes of antibiotic therapy in the treatment of spontaneous bacterial peritonitis in cirrhotic patients. SEARCH STRATEGY: We performed electronic searches in The Cochrane Hepato-Biliary Group Controlled Trials Register (July 2008), the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (Issue 3, 2008), MEDLINE (1950 to July 2008), EMBASE (1980 to July 2008), and Science Citation Index EXPANDED (1945 to July 2008). In addition, we handsearched the references of all identified studies and contacted the first author of each included trial. SELECTION CRITERIA: Randomised studies comparing different types of antibiotics for spontaneous bacterial peritonitis in cirrhotic patients. DATA COLLECTION AND ANALYSIS: Data were independently extracted from the trials by at least two authors. Peto odds ratios or average differences, with their 95% confidence intervals, were estimated. MAIN
RESULTS: This systematic review attempted to summarise evidence from randomised clinical trials on the treatment of spontaneous bacterial peritonitis. Thirteen studies were included; each one of them compared different antibiotics in their experimental and control groups. No meta-analyses could be performed, though data on the main outcomes were collected and analysed separately for each included trial. Currently, the evidence showing that lower dosage or short-term treatment with third generation cephalosporins is as effective as higher dosage or long-term treatment is weak. Oral quinolones could be considered an option for those with less severe manifestations of the disease. AUTHORS'
CONCLUSIONS: This review provides no clear evidence for the treatment of cirrhotic patients with spontaneous bacterial peritonitis. In practice, third generation cephalosporins have already been established as the standard treatment of spontaneous bacterial peritonitis, and it is clear, that empirical antibiotic therapy should be provided in any case. However, until large, well-conducted trials provide more information, practice will remain based on impression, not evidence.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19160207      PMCID: PMC7100568          DOI: 10.1002/14651858.CD002232.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  45 in total

1.  Spontaneous bacterial peritonitis--in-hospital mortality, predictors of survival, and health care costs from 1988 to 1998.

Authors:  P J Thuluvath; S Morss; R Thompson
Journal:  Am J Gastroenterol       Date:  2001-04       Impact factor: 10.864

2.  Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost.

Authors:  P Angeli; S Guarda; S Fasolato; E Miola; R Craighero; F Piccolo; C Antona; L Brollo; M Franchin; U Cillo; C Merkel; A Gatta
Journal:  Aliment Pharmacol Ther       Date:  2006-01-01       Impact factor: 8.171

3.  Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study.

Authors:  Lesley Wood; Matthias Egger; Lise Lotte Gluud; Kenneth F Schulz; Peter Jüni; Douglas G Altman; Christian Gluud; Richard M Martin; Anthony J G Wood; Jonathan A C Sterne
Journal:  BMJ       Date:  2008-03-03

4.  Spontaneous ascitic infection in different cirrhotic groups: prevalence, risk factors and the efficacy of cefotaxime therapy.

Authors:  S Kaymakoglu; H Eraksoy; A Okten; K Demir; S Calangu; Y Cakaloglu; G Boztas; F Besisik
Journal:  Eur J Gastroenterol Hepatol       Date:  1997-01       Impact factor: 2.566

5.  Improving the quality of reporting of randomized controlled trials. The CONSORT statement.

Authors:  C Begg; M Cho; S Eastwood; R Horton; D Moher; I Olkin; R Pitkin; D Rennie; K F Schulz; D Simel; D F Stroup
Journal:  JAMA       Date:  1996-08-28       Impact factor: 56.272

6.  Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis.

Authors:  Javier Fernández; Miquel Navasa; Juliá Gómez; Jordi Colmenero; Jordi Vila; Vicente Arroyo; Juan Rodés
Journal:  Hepatology       Date:  2002-01       Impact factor: 17.425

7.  Amoxicillin-clavulanic acid versus cefotaxime in the therapy of bacterial infections in cirrhotic patients.

Authors:  E Ricart; G Soriano; M T Novella; J Ortiz; M Sàbat; L Kolle; J Sola-Vera; J Miñana; J M Dedéu; C Gómez; J L Barrio; C Guarner
Journal:  J Hepatol       Date:  2000-04       Impact factor: 25.083

8.  Spontaneous bacterial peritonitis (SBP): clinical, laboratory, and prognostic features. A single-center experience.

Authors:  Anastasia C. Thanopoulou; John S. Koskinas; Stephanos J. Hadziyannis
Journal:  Eur J Intern Med       Date:  2002-05       Impact factor: 4.487

9.  Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis.

Authors:  Rubén Francés; Pedro Zapater; José M González-Navajas; Carlos Muñoz; Rocío Caño; Rocío Moreu; Sonia Pascual; Pablo Bellot; Miguel Pérez-Mateo; José Such
Journal:  Hepatology       Date:  2008-03       Impact factor: 17.425

10.  Intravenous ciprofloxacin and ceftazidime in serious infections. A prospective, controlled clinical trial with third-party blinding.

Authors:  J Sifuentes-Osornio; A Macías; R I Amieva; A Ramos; G M Ruiz-Palacios
Journal:  Am J Med       Date:  1989-11-30       Impact factor: 4.965

View more
  5 in total

1.  Portal hypertensive gastropathy: A systematic review of the pathophysiology, clinical presentation, natural history and therapy.

Authors:  Mihajlo Gjeorgjievski; Mitchell S Cappell
Journal:  World J Hepatol       Date:  2016-02-08

Review 2.  [Antibiotic therapy of intra-abdominal infections in the era of multiresistance].

Authors:  C Eckmann
Journal:  Chirurg       Date:  2016-01       Impact factor: 0.955

3.  The end-organ impairment in liver cirrhosis: appointments for critical care.

Authors:  Antonio Figueiredo; Francisco Romero-Bermejo; Rui Perdigoto; Paulo Marcelino
Journal:  Crit Care Res Pract       Date:  2012-05-16

4.  Antibiotic treatment for spontaneous bacterial peritonitis in people with decompensated liver cirrhosis: a network meta-analysis.

Authors:  Laura Iogna Prat; Peter Wilson; Suzanne C Freeman; Alex J Sutton; Nicola J Cooper; Davide Roccarina; Amine Benmassaoud; Maria Corina Plaz Torres; Neil Hawkins; Maxine Cowlin; Elisabeth Jane Milne; Douglas Thorburn; Chavdar S Pavlov; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2019-09-16

5.  Spontaneous bacterial peritonitis caused by Campylobacter Coli in cirrhotic patient: A rare case report (CARE-compliant).

Authors:  Cheng-Hui Wang; Ting-Han Tai; Shih-Yen Weng; Shin-Wen Yeh; Sheng-Jie Shiue; Ganbolor Jargalsaikhan; Ming-Shun Wu
Journal:  Medicine (Baltimore)       Date:  2020-05-22       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.